Search

Your search keyword '"Scorletti, Eleonora"' showing total 184 results
Start Over Author "Scorletti, Eleonora"
184 results on '"Scorletti, Eleonora"'

5. A missense variant in human perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice

Author

Scorletti, Eleonora, Saiman, Yedidya, Jeon, Sookyoung, Schneider, Carolin V., Buyco, Delfin G., Lin, Chelsea, Himes, Blanca E., Mesaros, Clementina A., Vujkovic, Marijana, Creasy, Kate Townsend, Furth, Emma E., Billheimer, Jeffrey T., Hand, Nicholas J., Kaplan, David E., Chang, Kyong-Mi, Tsao, Philip S., Lynch, Julie A., Dempsey, Joseph L., Harkin, Julia, Bayen, Susovon, Conlon, Donna, Guerraty, Marie, Phillips, Michael C., Rader, Daniel J., and Carr, Rotonya M.

Published
2024
Full Text
View/download PDF

7. Large-scale identification of undiagnosed hepatic steatosis using natural language processing

Author

Schneider, Carolin V., Li, Tang, Zhang, David, Mezina, Anya I., Rattan, Puru, Huang, Helen, Creasy, Kate Townsend, Scorletti, Eleonora, Zandvakili, Inuk, Vujkovic, Marijana, Hehl, Leonida, Fiksel, Jacob, Park, Joseph, Wangensteen, Kirk, Risman, Marjorie, Chang, Kyong-Mi, Serper, Marina, Carr, Rotonya M., Schneider, Kai Markus, Chen, Jinbo, and Rader, Daniel J.

Published
2023
Full Text
View/download PDF

9. Effect of omega-3 fatty acids in non-alcoholic fatty liver disease

Author

Scorletti, Eleonora, Byrne, Christopher, and Calder, Philip

Subjects
616.3
Abstract

The first chapter (Introduction) of the thesis summarises the pathogenesis of NAFLD and its associated risk factors such as type 2 diabetes and cardiovascular disease. Moreover, it describes: a) the potential beneficial effects of long chain omega-3 fatty acid treatment [docosahexaenoic acid (DHA) plus eicosapentaenoic acid (EPA)] in NAFLD; b) the effect of genotypes patatin-like phospholipase domain-containing protein-3 (PNPLA3 I148M) and the transmembrane 6 superfamily member 2 protein (TM6SF2 E167K), on the level of DHA and EPA enrichment and end of study liver fat percentage after DHA+EPA treatment; and c) the effect of fatty acid desaturase (FADS) and Elongase (ELOVL) polymorphisms influencing omega-3 fatty acid metabolism. The second chapter describes the overall aim of this thesis. The aim of my research was to investigate in patients with NAFLD: a) the effect of long-chain omega-3 fatty acid treatment on liver fat percentage and liver fibrosis biomarkers; b) the effect of genotypes influencing NAFLD severity on treatment with DHA+EPA; and c) the effect of genotypes influencing omega-3 fatty acid metabolism in NAFLD. The third chapter describes in details the design and methods used in my research. Chapter four highlights my novel results from the WELCOME study. This chapter describes the baseline and end of study characteristics of the WELCOME study participants and shows the results of the DHA+EPA treatment on liver fat percentage and liver fibrosis biomarkers. This chapter also describes the association between DHA erythrocyte enrichment and decrease in liver fat percentage after DHA+EPA treatment. Chapter five illustrates the association between PNPLA3 I148M and DHA erythrocyte enrichment percentage and end of study liver fat percentage after DHA+EPA treatment. The chapter shows that PNPLA3 I148M was associated with higher end of study liver fat percentage and lower DHA tissue enrichment. Chapter six shows the negative association between FADS polymorphisms and omega-3 fatty acid metabolism in NAFLD. The chapter also shows that there was a gene-DHA+EPA interaction between the minor allele of the FADS1 rs174556 and Δ-5 desaturase activity after treatment with DHA+EPA. Finally, chapter seven, summarises my results in the context of current evidence and knowledge about the subject matter.

Published
2017

10. Bile Acids as Emerging Players at the Intersection of Steatotic Liver Disease and Cardiovascular Diseases.

Author

Bilson, Josh, Scorletti, Eleonora, Swann, Jonathan R., and Byrne, Christopher D.

Subjects
*CARDIOVASCULAR diseases, *METABOLIC disorders, *LIVER diseases, *BILE acids, *LIPID metabolism
Abstract

Affecting approximately 25% of the global population, steatotic liver disease (SLD) poses a significant health concern. SLD ranges from simple steatosis to metabolic dysfunction-associated steatohepatitis and fibrosis with a risk of severe liver complications such as cirrhosis and hepatocellular carcinoma. SLD is associated with obesity, atherogenic dyslipidaemia, and insulin resistance, increasing cardiovascular risks. As such, identifying SLD is vital for cardiovascular disease (CVD) prevention and treatment. Bile acids (BAs) have critical roles in lipid digestion and are signalling molecules regulating glucose and lipid metabolism and influencing gut microbiota balance. BAs have been identified as critical mediators in cardiovascular health, influencing vascular tone, cholesterol homeostasis, and inflammatory responses. The cardio-protective or harmful effects of BAs depend on their concentration and composition in circulation. The effects of certain BAs occur through the activation of a group of receptors, which reduce atherosclerosis and modulate cardiac functions. Thus, manipulating BA receptors could offer new avenues for treating not only liver diseases but also CVDs linked to metabolic dysfunctions. In conclusion, this review discusses the intricate interplay between BAs, metabolic pathways, and hepatic and extrahepatic diseases. We also highlight the necessity for further research to improve our understanding of how modifying BA characteristics affects or ameliorates disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. A Missense Variant in Human Perilipin 2 (Plin2 Ser251pro) Reduces Hepatic Steatosis In Mice

Author

Scorletti, Eleonora, primary, Saiman, Yedidya, additional, Jeon, Sookyoung, additional, Schneider, Carolin V., additional, Buyco, Delfin G., additional, Lin, Chelsea, additional, Himes, Blanca E., additional, Mesaros, Clementina A., additional, Vujkovic, Marijana, additional, Creasy, Kate Townsend, additional, Furth, Emma E., additional, Billheimer, Jeffrey T., additional, Hand, Nicholas J., additional, Kaplan, David E., additional, Chang, Kyong-Mi, additional, Tsao, Philip S., additional, Lynch, Julie A., additional, Dempsey, Joseph L., additional, Harkin, Julia, additional, Bayen, Susovon, additional, Conlon, Donna, additional, Guerraty, Marie, additional, Phillips, Michael C., additional, Rader, Daniel J., additional, and Carr, Rotonya M., additional

Published
2023
Full Text
View/download PDF

16. Aspirin is associated with a reduced incidence of liver disease in men

Author

Vell, Mara Sophie, primary, Krishnan, Arunkumar, additional, Wangensteen, Kirk, additional, Serper, Marina, additional, Seeling, Katharina Sophie, additional, Hehl, Leonida, additional, Rendel, Miriam Daphne, additional, Zandvakili, Inuk, additional, Vujkovic, Marijana, additional, Scorletti, Eleonora, additional, Creasy, Kate Townsend, additional, Trautwein, Christian, additional, Rader, Daniel James, additional, Alqahtani, Saleh, additional, Schneider, Kai Markus, additional, and Schneider, Carolin Victoria, additional

Published
2023
Full Text
View/download PDF

17. Omega-3 intake is associated with liver disease protection

Author

Vell, Mara Sophie, primary, Creasy, Kate Townsend, additional, Scorletti, Eleonora, additional, Seeling, Katharina Sophie, additional, Hehl, Leonida, additional, Rendel, Miriam Daphne, additional, Schneider, Kai Markus, additional, and Schneider, Carolin Victoria, additional

Published
2023
Full Text
View/download PDF

18. Association of Statin Use With Risk of Liver Disease, Hepatocellular Carcinoma, and Liver-Related Mortality

Author

Vell, Mara Sophie, primary, Loomba, Rohit, additional, Krishnan, Arunkumar, additional, Wangensteen, Kirk J., additional, Trebicka, Jonel, additional, Creasy, Kate Townsend, additional, Trautwein, Christian, additional, Scorletti, Eleonora, additional, Seeling, Katharina Sophie, additional, Hehl, Leonida, additional, Rendel, Miriam Daphne, additional, Zandvakili, Inuk, additional, Li, Tang, additional, Chen, Jinbo, additional, Vujkovic, Marijana, additional, Alqahtani, Saleh, additional, Rader, Daniel James, additional, Schneider, Kai Markus, additional, and Schneider, Carolin Victoria, additional

Published
2023
Full Text
View/download PDF

19. Concomitant western diet and chronic-binge alcohol dysregulate hepatic metabolism

Author

Buyco, Delfin Gerard, primary, Dempsey, Joseph L., additional, Scorletti, Eleonora, additional, Jeon, Sookyoung, additional, Lin, Chelsea, additional, Harkin, Julia, additional, Bayen, Susovon, additional, Furth, Emma E., additional, Martin, Jasmin, additional, Delima, Monique, additional, Hooks, Royce, additional, Sostre-Colón, Jaimarie, additional, Gharib, Sina A., additional, Titchenell, Paul M., additional, and Carr, Rotonya M., additional

Published
2023
Full Text
View/download PDF

23. Ceramide synthase 6 (CerS6) promotes alcohol-induced fatty liver by promoting metabolic dysfunction and upregulating lipid droplet-associated proteins

Author

Jeon, Sookyoung, primary, Scorletti, Eleonora, additional, Buyco, Delfin, additional, Lin, Chelsea, additional, Saiman, Yedidya, additional, Martin, Jasmin, additional, Hooks, Royce, additional, Ogretmen, Besim, additional, Argemi, Josepmaria, additional, Melo, Luma, additional, Bataller, Ramon, additional, and Carr, Rotonya M., additional

Published
2022
Full Text
View/download PDF

26. A coding variant in the microsomal triglyceride transfer protein reduces both hepatic steatosis and plasma lipids.

Author

Schneider, Carolin V., Hehl, Leonida, Creasy, Kate T., Vitali, Cecilia, Vell, Mara S., Vujkovic, Marijana, Park, Joseph, Scorletti, Eleonora, Seeling, Katharina S., Rendel, Miriam D., Conlon, Donna M., Huang, Helen, Zandvakili, Inuk, Valmiki, Swati, Schneider, Kai Markus, Hussain, M. Mahmood, and Rader, Daniel J.

Subjects
FATTY liver, BLOOD lipids, MISSENSE mutation, PROTEINS, TRIGLYCERIDES
Abstract

Summary: Background: Genetic inactivation and pharmacologic inhibition of the microsomal triglyceride transfer protein (MTP; gene name MTTP) inhibits hepatic secretion of VLDL, thereby reducing serum lipids and apoB at the expense of increasing hepatic steatosis. Aim: To examine the effects of missense variants in MTTP on hepatic and circulating lipids. Methods: We analysed the association of MTTP missense variants with metabolic, hepatic and clinical phenotypes in the Penn Medicine Biobank (PMBB; n = 37,960) and the UKBiobank (UKB; n = 451,444). Results: We analysed 24 missense variants in MTTP in PMBB for association with biopsy‐proven hepatic steatosis and found that an isoleucine 128 to threonine variant (I128T: rs3816873‐A, frequency 26%) was associated with reduced steatosis (p < 0.001). PMBB subjects with imaging‐proven steatosis also revealed significantly fewer carriers of MTTP I128T compared to controls. Analysis in UKB also showed that MTTP I128T was associated with reduced risk of hepatic steatosis. Unexpectedly, MTTP I128T was found to be associated with reduced plasma levels of LDL‐cholesterol and apoB (all p < 0.001). Functional studies indicated that MTTP I128T is neither a classic loss nor gain of function allele. Conclusions: MTTP I128T is associated with reduced hepatic steatosis as well as reduced plasma lipids and apoB. This paradoxical profile is not consistent with a simple gain or loss of function in MTP activity and suggests a more complex effect on MTP function. Further investigation of MTTP I128T will provide insight into the structure–function of MTP and potentially new approaches to modulate MTP activity that could both reduce hepatic and circulating lipids. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD.

Author

UCL - SSS/LDRI - Louvain Drug Research Institute, Bilson, Josh, Scorletti, Eleonora, Bindels, Laure B., Afolabi, Paul R, Targher, Giovanni, Calder, Philip C, Sethi, Jaswinder K, Byrne, Christopher D, UCL - SSS/LDRI - Louvain Drug Research Institute, Bilson, Josh, Scorletti, Eleonora, Bindels, Laure B., Afolabi, Paul R, Targher, Giovanni, Calder, Philip C, Sethi, Jaswinder K, and Byrne, Christopher D

Abstract

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a strong risk factor for liver fibrosis in non-alcoholic fatty liver disease (NAFLD). It remains uncertain why T2DM increases the risk of liver fibrosis. It has been suggested that growth differentiation factor-15 (GDF-15) concentrations increase the risk of liver fibrosis. We aimed to investigate (a) whether GDF-15 concentrations were associated with liver fibrosis and involved in the relationship between T2DM and liver fibrosis and (b) what factors linked with T2DM are associated with increased GDF-15 concentrations. METHODS: Ninety-nine patients with NAFLD (61% men, 42.4% T2DM) were studied. Serum GDF-15 concentrations were measured by electro-chemiluminescence immunoassay. Vibration-controlled transient elastography (VCTE)-validated thresholds were used to assess liver fibrosis. Regression modelling, receiver operator characteristic curve analysis and Sobel test statistics were used to test associations, risk predictors and the involvement of GDF-15 in the relationship between T2DM and liver fibrosis, respectively. RESULTS: Patients with NAFLD and T2DM (n = 42) had higher serum GDF-15 concentrations [mean (SD): 1271.0 (902.1) vs. 640.3 (332.5) pg/ml, p < 0.0001], and a higher proportion had VCTE assessed ≥F2 fibrosis (48.8 vs. 23.2%, p = 0.01) than those without T2DM. GDF-15 was independently associated with liver fibrosis (p = 0.001), and GDF-15 was the most important single factor predicting ≥F2 or ≥F3 fibrosis (≥F2 fibrosis AUROC 0.75, (95% CI 0.63-0.86), p < 0.001, with sensitivity, specificity, positive predictive (PPV) and negative predictive (NPV) values of 56.3%, 86.9%, 69.2% and 79.1%, respectively). GDF-15 was involved in the association between T2DM and ≥F2 fibrosis (Sobel test statistic 2.90, p = 0.004). Other factors associated with T2DM explained 60% of the variance in GDF-15 concentrations (p < 0.0001). HbA1c concentrations alone explained 30% of the variance (p < 0.0001). CONCLUSIONS: GDF-15 concentr

Published
2021

34. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials

Author

Mantovani, Alessandro, Byrne, Christopher, Scorletti, Eleonora, Mantzoros, Christos S., and Targher, Giovanni

Subjects
medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Gastroenterology, digestive system, Glucagon-Like Peptide-1 Receptor, law.invention, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Endocrinology, Randomized controlled trial, law, Non-alcoholic Fatty Liver Disease, Internal medicine, Diabetes mellitus, NAFLD, Internal Medicine, Medicine, Humans, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors, Randomized Controlled Trials as Topic, Dipeptidyl-Peptidase IV Inhibitors, business.industry, Fatty liver, NASH, nutritional and metabolic diseases, General Medicine, medicine.disease, Metformin, digestive system diseases, Anti-hyperglycaemic drugs, Treatment Outcome, Diabetes Mellitus, Type 2, Thiazolidinediones, Steatohepatitis, business, Pioglitazone, medicine.drug
Abstract

AimThere are no approved drugs for the treatment of non-alcoholic fatty liver disease (NAFLD). However, many randomized controlled trials (RCT) have examined the effect of anti-hyperglycaemic agents on NAFLD in patients with and without type 2 diabetes mellitus (T2DM), since both T2DM and insulin resistance are closely linked to this burdensome liver disease.MethodsWe systematically searched publication databases using predefined keywords to identify head-to-head or placebo-controlled RCTs (published until September 30, 2019) of NAFLD individuals testing the efficacy of anti-hyperglycaemic drugs to specifically treat NAFLD or non-alcoholic steatohepatitis (NASH). Outcomes of interest included changes in serum liver enzyme levels, liver fat, liver fibrosis, or histologic resolution of NASH.ResultsWe included 29 RCTs involving a total of 2,617 individuals (∼45% had T2DM) that have used metformin (n = 6 studies), glitazones (n = 8 studies), glucagon-like peptide-1 receptor agonists (n = 6 studies), dipeptidyl peptidase-4 inhibitors (n = 4 studies) or sodium-glucose cotransporter-2 inhibitors (n = 7 studies) to treat NAFLD. Although most anti-hyperglycaemic drugs improved serum liver enzyme levels, only glitazones (especially pioglitazone) and liraglutide showed an improvement of histologic features of NAFLD, with a mild beneficial effect also on liver fibrosis for pioglitazone only.ConclusionRCT evidence supports the efficacy of some anti-hyperglycaemic agents (especially pioglitazone) in patients with NAFLD or NASH, though weight gain with pioglitazone may warrant caution. Further well-designed RCTs are needed to better characterize the efficacy and safety of monotherapy and combination therapy with anti-hyperglycaemic agents in patients with NAFLD.

Published
2020

35. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study

Author

Scorletti, Eleonora, Bhatia, Lokpal, McCormick, Keith G., Clough, Geraldine F., Nash, Kathryn, Hodson, Leanne, Moyses, Helen E., Calder, Philip C., Byrne, Christopher D., Sheron, Nick, Wright, Mark, Curzen, Nick, Rakhit, Dhrubo, Peebles, Charles, Darekar, Angela, Fletcher, Alison, Bateman, Adrian, Williams, Elizabeth, Aspinall, Richard, Fowell, Andrew, Richardson, Tristan, Li Voon Chong, J. S.W., and Al-Mrayat, Maén

Published
2014
Full Text
View/download PDF

36. The common p.Ile291Val variant of ERLIN1enhances TM6SF2 function and is associated with protection against MASLD

Author

Rendel, Miriam Daphne, Vitali, Cecilia, Creasy, Kate Townsend, Zhang, David, Scorletti, Eleonora, Huang, Helen, Seeling, Katharina Sophie, Park, Joseph, Hehl, Leonida, Vell, Mara Sophie, Conlon, Donna, Hayat, Sikander, Phillips, Michael C., Schneider, Kai Markus, Rader, Daniel J., and Schneider, Carolin Victoria

Abstract

The ERLIN1p.Ile291Val single-nucleotide polymorphism (rs2862954) is associated with protection from steatotic liver disease (SLD), but effects of this variant on metabolic phenotypes remain uncertain.

Published
2024
Full Text
View/download PDF

38. A new perspective on NAFLD: Focusing on lipid droplets.

Author

Scorletti, Eleonora and Carr, Rotonya M.

Subjects
*HEPATIC fibrosis, *NON-alcoholic fatty liver disease, *ENDOPLASMIC reticulum, *LIVER diseases, *LIVER cells
Abstract

Lipid droplets (LDs) are complex and metabolically active organelles. They are composed of a neutral lipid core surrounded by a monolayer of phospholipids and proteins. LD accumulation in hepatocytes is the distinctive characteristic of non-alcoholic fatty liver disease (NAFLD), which is a chronic, heterogeneous liver condition that can progress to liver fibrosis and hepatocellular carcinoma. Though recent research has improved our understanding of the mechanisms linking LD accumulation to NAFLD progression, numerous aspects of LD biology are either poorly understood or unknown. In this review, we provide a description of several key mechanisms that contribute to LD accumulation in hepatocytes, favouring NAFLD progression. First, we highlight the importance of LD architecture and describe how the dysregulation of LD biogenesis leads to endoplasmic reticulum stress and inflammation. This is followed by an analysis of the causal nexus that exists between LD proteome composition and LD degradation. Finally, we describe how the increase in size of LDs causes activation of hepatic stellate cells, leading to liver fibrosis and hepatocellular carcinoma. We conclude that acquiring a more sophisticated understanding of LD biology will provide crucial insights into the heterogeneity of NAFLD and assist in the development of therapeutic approaches for this liver disease. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

40. Liver-specific ceramide reduction alleviates steatosis and insulin resistance in alcohol-fed mice

Author

Correnti, Jason, primary, Lin, Chelsea, additional, Brettschneider, Jascha, additional, Kuriakose, Amy, additional, Jeon, Sookyoung, additional, Scorletti, Eleonora, additional, Oranu, Amanke, additional, McIver-Jenkins, Dru, additional, Kaneza, Isabelle, additional, Buyco, Delfin, additional, Saiman, Yedidya, additional, Furth, Emma E., additional, Argemi, Josepmaria, additional, Bataller, Ramon, additional, Holland, William L., additional, and Carr, Rotonya M., additional

Published
2020
Full Text
View/download PDF

42. Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease

Author

Scorletti, Eleonora, primary, Afolabi, Paul R., additional, Miles, Elizabeth A., additional, Smith, Debbie E., additional, Almehmadi, Amal, additional, Alshathry, Albandri, additional, Childs, Caroline E., additional, Del Fabbro, Stefania, additional, Bilson, Josh, additional, Moyses, Helen E., additional, Clough, Geraldine F., additional, Sethi, Jaswinder K., additional, Patel, Janisha, additional, Wright, Mark, additional, Breen, David J., additional, Peebles, Charles, additional, Darekar, Angela, additional, Aspinall, Richard, additional, Fowell, Andrew J., additional, Dowman, Joanna K., additional, Nobili, Valerio, additional, Targher, Giovanni, additional, Delzenne, Nathalie M., additional, Bindels, Laure B., additional, Calder, Philip C., additional, and Byrne, Christopher D., additional

Published
2020
Full Text
View/download PDF

44. Multi-domain analysis of microvascular flow motion dynamics

Author

Chipperfield, Andrew, Thanaj, Marjola, Scorletti, Eleonora, Byrne, Christopher, and Clough, Geraldine

Abstract

Objective: to determine whether analysis of microvascular network perfusion using complexitybased methods can discriminate between groups of individuals at an increased risk of developing CVD.Methods: data were obtained from laser Doppler recordings of skin blood flux at the forearm in 50 participants with non-alcoholic fatty liver disease grouped for absence (n=28) or presence (n=14) of type 2 diabetes and use of calcium channel blocker medication (n=8). Power spectral density was evaluated and Lempel-Ziv complexity determined to quantify signal information content at single and multiple time-scales to account for the different processes modulating network perfusion.Results: complexity was associated with dilatory capacity and respiration and negatively with baseline blood flux and cardiac band power. The relationship between the modulators of flowmotion and complexity of blood flux is shown to change with time-scale improving discrimination between groups. Multiscale Lempel-Ziv achieved best classification accuracy of 86.1%.Conclusions: time and frequency domain measures alone are insufficient to discriminate between groups. As CVD risk increases, the degree of complexity of the blood flux signal reduces, indicative of a reduced temporal activity and heterogeneous distribution of blood flow within the microvascular network sampled. Complexity-based methods, particularly multiscale variants, are shown to have good discriminatory capabilities.

Published
2019

45. Liver zonation in children with NAFLD: associations with dietary fructose and uric acid concentrations

Author

Nobili, Valerio, Mosca, Antonella, De Vito, Rita, Raponi, Massimiliano, Scorletti, Eleonora, and Byrne, Christopher D.

Abstract

Background & Aims As dietary components are delivered directly to the periportal zone of the liver lobule, there is the potential for greater injury in this zone (zone 1) compared to the perivenous zone (zone 3). We investigated the associations between dietary fructose consumption and uric acid concentrations and differential zonal injury in periportal and perivenous zones. Methods A total of 271 children's histological images were scored in 5 periportal and 5 perivenous zones for steatosis, ballooning, inflammation and fibrosis severity. Dietary fructose consumption (g/d) was assessed and uric acid measured in serum. Logistic regression was undertaken to test associations between both high fructose consumption and hyperuricaemia, and histological disease in periportal and perivenous zones. Results Children with a mean age of 12.5 years were included in the study. Inflammation (mean ± SD) was increased in the periportal vs perivenous zones (0.78 ± 0.43 vs 0.41 ± 0.48, P = .041). There were non-significant trends towards greater steatosis, ballooning and fibrosis in the periportal zone. In the fully adjusted models, high fructose intake was associated with disease in both zones. Example for periportal and perivenous zones, respectively, steatosis 1.56 (1.12, 2.49) and 1.21 (1.09, 2.73); inflammation 4.29 (2.31, 5.88) and 3.69 (2.14, 4.56); and fibrosis 2.72 (1.43, 3.76) and 1.96 (1.24, 2.37). Hyperuricaemia (uric acid ≥5.9 mg/dL) was associated with inflammation in the periportal zone 1.71 (1.17, 2.35); and was associated with steatosis and fibrosis in both zones; for example, for periportal and perivenous zones, respectively, steatosis 2.98 (1.65, 3.23) and 1.14 (1.05, 1.99); and fibrosis, 2.65 (1.35, 2.99) and 1.31 (1.13, 2.17). Conclusions High fructose consumption is associated with disease severity in both lobular zones and hyperuricaemia may be associated with more severe disease in the periportal zone.

Published
2018

46. Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: Plasma proteomics in the randomized WELCOME* trial

Author

Manousopoulou, Antigoni, primary, Scorletti, Eleonora, additional, Smith, Debbie E., additional, Teng, Jie, additional, Fotopoulos, Miltiadis, additional, Roumeliotis, Theodoros I., additional, Clough, Geraldine F., additional, Calder, Philip C., additional, Byrne, Christopher D., additional, and Garbis, Spiros D., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results